![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
No Detectable Tenofovir Resistance With Tenofovir
Disoproxil Fumarate (TDF) or TDF+Emtricitabine (FTC/TDF)
Through 96 Weeks in Lamivudine-Resistant CHB Patients
|
|
|
Reported by Jules Levin
Asian Pacific Association for the Study of the Liver (APASL) Liver Week, June 6-10, 2013, Singapore
Edward Gane1, Amoreena C. Corsa2, Yang Liu2, Ben C. Mitchell2, John F. Flaherty2,
Michael D. Miller2, Kathryn M. Kitrinos2, Scott Fung3
1New Zealand Liver Transplant Unit, Auckland, New Zealand; 2Gilead Sciences, Inc., Foster City, CA, USA; 3Toronto General Hospital, Toronto, Ontario, Canada
![APASL1.gif](../images/061913/061913-7/APASL1.gif)
![APASL2.gif](../images/061913/061913-7/APASL2.gif)
![APASL3.gif](../images/061913/061913-7/APASL3.gif)
![APASL4.gif](../images/061913/061913-7/APASL4.gif)
![APASL5.gif](../images/061913/061913-7/APASL5.gif)
![APASL6.gif](../images/061913/061913-7/APASL6.gif)
![APASL7.gif](../images/061913/061913-7/APASL7.gif)
![APASL8.gif](../images/061913/061913-7/APASL8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|